Gestational diabetes, glycemic management trajectories, and offspring growth patterns and obesity risk
Chehab RF, Greenberg MB, Lee C, et al.
Diabetes Care. Pub. online 4 Mar 2026.
Leggi
Comparative effectiveness of tirzepatide versus dulaglutide or semaglutide on major cardiovascular events in type 2 diabetes and cardiovascular disease: insights from two target-trial emulations
Ostrominski JW, Ortega-Montiel J, Wexler DJ, et al.
Diabetes Care. Pub. online 2 Mar 2026.
Leggi
Semaglutide in peripheral artery disease and diabetes by baseline disease severity and age: the STRIDE trial
Nordanstig J, Arslan EG, Catarig AM, et al.
Eur Heart J. Pub. online 5 Mar 2026.
Leggi
Everyone or just some? cost-effectiveness of general population versus targeted screening strategies for type 1 diabetes in Canada
Mital S, Schatz DA, Haller MJ, et al.
Diabetes Care. Pub. online 2 Mar 2026.
Leggi
Small extracellular vesicle external surface adiponectin-mediated adipocytes/cardiomyocytes communication in diabetic ischemic heart failure
Zhang Z, Zhu D, Liu C, et al.
Circulation. Pub. online 2 Mar 2026.
Leggi
NUOVO PERCORSO SCIENTIFIC TALK E OCCHIO AL TRIAL AMD 2026
Carissimi Soci, primo percorso 2026 in combinazione Scientific Talk e Occhio al Trial AMD: “Colmare il gap tra evidenza, linee guida ed innovazione digitale nella cura del DMT2”. L’iniziativa, accreditata ECM, prevede tre appuntamenti: 25 Marzo 1° Scientific Talk “Prevenzione del rischio: Empaglifozin come strategia precoce per la protezione cardiovascolare e renale” M. Manunta…
Leggi
Joint TOS/OMA/OAC expert guidance statement on the pharmacological management of United States adults with overweight or obesity using the GRADE approach
Alexander L, Purnell JQ, Burridge K, et al.
Obesity (Silver Spring). Pub. online 5 Mar 2026.
Leggi
Finerenone in type 1 diabetes and chronic kidney disease
Heerspink HJL, Birkenfeld AL, Cherney DZI, et al.
N Engl J Med. Pub. online 5 Mar 2026.
Leggi
Obesity and metabolic syndrome predict polyneuropathy over 5 years in recent-onset type 2 diabetes and normal glucose tolerance
Sipola G, Strom A, Wagner R, et al.
Diabetes Metab Res Rev. Pub. online 3 Mar 2026.
Leggi
Additive cardiorenal benefits of finerenone and SGLT2 inhibitor combination therapy in diabetic CKD: a propensity-matched real-world study
Mortada I, Lee A, Sahu A, et al.
Am J Cardiol. Pub. online 27 Feb 2026.
Leggi